Posted by Michael Wonder on 03 Sep 2025
Health Canada approves Elahere for certain types of platinum-resistant ovarian cancers
2 September 2025 - Elahere received approval through Health Canada's priority review process, based on data from the pivotal MIRASOL Phase 3 trial, establishing it as a potential new standard of care for folate receptor alpha positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Today, AbbVie has announced that under the Priority Review process, Health Canada has approved Elahere (mirvetuximab soravtansine for injection), an antibody-drug conjugate, for the treatment of adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
